Update on the management of triple negative breast cancer (TNBC)

Abstract

Introduction: Triple negative breast cancer (TNBC) corresponds to about 15% -20% of all carcinomas and is associated with a high risk of relapse, decreased disease-free survival and poor prognosis. TNBC is characterized by a biological and clinical heterogeneity, making it an extremely complex affair.
Aim: to present modern therapeutic options to treat TNBC.
Material and Method: Systematic review was carried out for a two years period, 2021 - 2023, in the PubMed, Scopus, Science Direct and Google Scholar database, setting specific criteria for integration and exclusion.
Results: Several therapeutic substances such as Capecitabine, carboplatin and Taxanes are suggested for the treatment of triple negative breast cancer. Among the new therapies that have been approved for the management of TNBC, immunotherapy shows great potential.
Conclusions: In the coming years through the complete understanding of the development mechanism and the evolution of triple negative breast cancer, there are expected to be newer and up -to -date guidelines for its management and treatment. This requires interdisciplinary cooperation and support so that patients eventually receive appropriate, safe and targeted treatments.